CHICAGO - A multicenter study has found the cost savings of the two leading non-invasive methods for detecting coronary artery disease (CAD) varies based on the patient's heart history. The study found that patients who underwent coronary computed tomographic angiography (CCTA), without a prior diagnosis of CAD, incurred costs $603 lower (per patient average) than those who underwent myocardial perfusion imaging (MPI or SPECT). Both groups had equal clinical outcomes. However, patients with known CAD who underwent MPI incurred healthcare costs $2,451 lower (per patient average) than CCTA patients with equal clinical outcomes. These results suggest that CCTA may be a cost-efficient alternative in patients without a prior CAD diagnosis.

New York Presbyterian/Weill Cornell Cardiologist Dr. James K. Min presented the findings Tuesday at the 57th Annual Meeting of the American College of Cardiology in Chicago. "These are exciting data," said Min. "This provides an initial foundation to suggest that CCTA may be used as a cost-efficient alternative to nuclear stress testing for evaluation of patients with suspected coronary artery disease."

Recently, the Centers for Medicare and Medicaid Services (CMS) assigned transaction codes (T-codes) for CT dedicated to coronary angiography. Looking at multicenter payer claims from five health plans with memberships of at least 10 million people, the study examined cost effectiveness for patients undergoing CCT under "T-codes," compared to matched patients undergoing MPI testing.
Researchers collected data for 142,535 patients who underwent CCT or MPI for 9 months before and after the test. Pre-test cardiac risk was assessed by cardiac risk factors and medications. MPI patients were matched to CCT patients using 11 categories of demographic and risk states. Cost and clinical effectiveness were measured in both downstream CAD costs and clinical events including myocardial infarction (MI), angina and CAD-related hospitalization.

About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.

GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

More Industry Headlines